SUPN Past Earnings image   This SUPN past earnings page last updated 11/10/2022
SUPN Past Earnings
PeriodPast Earnings DateGAAP
Q3 202211/8/20220.030
Q2 20228/4/20220.140
Q1 20225/9/20220.430
Q4 20214/13/20220.040
Q3 202111/3/20210.400
Q2 20218/4/20210.430
Q1 20215/5/20210.110
Q4 20202/25/20210.570
Q3 202011/3/20200.740
Q2 20208/18/20200.650
Q1 20205/5/20200.400
Q4 20192/25/20200.620
Q3 201911/5/20190.540
Q2 20198/6/20190.610
Q1 20195/7/20190.340
Q4 20182/26/20190.48
Q3 201811/6/20180.52
Q2 20188/7/20180.57
Q1 20185/8/20180.49
Q4 20172/27/20180.44
Q3 201711/6/20170.29
Q2 20178/2/20170.32
Q1 20175/9/20170.19
Q4 20162/28/20170.26
Q3 20161/20/20170.37
Q2 20168/2/20160.18
Q1 20165/3/20160.08
Q4 20153/2/20160.14
Q3 201511/3/20150.08
Q2 20158/4/20150.03
Q1 20155/5/20150.02
Q4 20143/10/20150.08
Q3 201411/11/20140.39
Q2 20148/11/20140.08
Q1 20145/5/2014-0.38
Q4 20133/12/2014-0.65
Q3 201311/12/2013-0.78
Q2 20138/13/2013-0.89
Q1 20135/13/2013-0.6
Q4 20123/14/2013-0.51
SUPN Past Revenue
PeriodPast Earnings DateGAAP
Q3 202211/8/20220.18B
Q2 20228/4/20220.17B
Q1 20225/9/20220.15B
Q4 20214/13/20220.16B
Q3 202111/3/20210.15B
Q2 20218/4/20210.14B
Q1 20215/5/20210.13B
Q4 20202/25/20210.14B
Q3 202011/3/20200.16B
Q2 20208/18/20200.13B
Q1 20205/5/20200.09B
Q4 20192/25/20200.10B
Q3 201911/5/20190.10B
Q2 20198/6/20190.10B
Q1 20195/7/20190.09B
Q4 20182/26/2019115.93M
Q3 201811/6/2018103.00M
Q2 20188/7/201899.54M
Q1 20185/8/201890.43M
Q4 20172/27/201888.44M
Q3 201711/6/201780.40M
Q2 20178/2/201775.83M
Q1 20175/9/201757.58M
Q4 20162/28/201762.37M
Q3 20161/20/201756.80M
Q2 20168/2/201650.42M
Q1 20165/3/201643.08M
Q4 20153/2/201642.66M
Q3 201511/3/201538.59M
Q2 20158/4/201535.05M
Q1 20155/5/201528.13M
Q4 20143/10/201530.08M
Q3 201411/11/201452.50M
Q2 20148/11/201427.60M
Q1 20145/5/20149.08M
Q4 20133/12/201410.30M
Q3 201311/12/20131.26M
Q2 20138/13/2013281000
Q1 20135/13/2013147000
Q4 20123/14/2013109000
Quotes delayed 20 minutes

Email EnvelopeFree SUPN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Supernus Pharmaceuticals (SUPN) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

SURF Past Earnings
SVRA Past Earnings
SWAV Past Earnings
SWTX Past Earnings
SYBX Past Earnings
SYK Past Earnings
SYNH Past Earnings
SYRS Past Earnings
TALS Past Earnings
TARA Past Earnings

SUPN Past Earnings Q&A

What was the best and worst SUPN past earnings results?
For Supernus Pharmaceuticals, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest SUPN past earnings result in our data set was 0.740/share posted in Q3 2020, while the lowest was in Q2 2013 when SUPN posted -0.89/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q3 2022 when SUPN reported 0.18B in revenue, while the quarter with the lowest revenue in our data set was Q4 2012 at 109000 of revenue.

  Suggested answer: There are 40 SUPN past earnings results in our data set.

On this page we presented the SUPN past earnings date information for Supernus Pharmaceuticals. Reviewing that SUPN Past Earnings for the company, we see that the highest past earnings result in our data set was in Q3 2020, when SUPN posted gaap of 0.740/share. Meanwhile the lowest SUPN past earnings result was in Q2 2013, when SUPN posted gaap of -0.89/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q3 2022 when SUPN reported 0.18B in revenue, while the smallest revenue quarter was Q4 2012 when SUPN reported 109000 in revenue.

Any self directed investor doing their due diligence on SUPN or any other given stock can benefit from researching all of the Supernus Pharmaceuticals past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate Supernus Pharmaceuticals past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for SUPN. Thanks for visiting, and the next time you need to research SUPN past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: SOPW Insider Buying, CLDX Historical Stock Prices, TGA Options Chain.

 

SUPN Past Earnings | www.PastEarnings.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in PastEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.